Crown Bioscience Strengthens Pre-Clinical Leadership Team with Senior Appointment
News Jul 03, 2015
Crown Bioscience, Inc., a leading global drug discovery and development service company has announced the appointment of Laurie Heilmann as the new Senior Vice President Global Strategy, Marketing Business Development. The new appointment coincides with a substantial increase in business growth and recent expansion and will act to further strengthen Crown’s global presence.
Bringing over 30 years’ experience in medical and life science services, Heilmann has extensive experience and a proven track record for building world class teams and consistently increasing sales results, profits, market share and new market development. Her multifaceted experience in medical devices, software, Phase I-IV clinical research and knowledge of FDA and sponsor requirements in the US, Europe, India and Asia will prove to be an important asset in Crown’s strategic expansion into the clinical services market.
Prior to joining Crown Bioscience, Heilmann has held several senior positions in prominent drug and device development companies, including American College of Radiology for profit imaging CRO, Image Metrix, Co-founder and Senior Vice President of Ockham Development Group. Heilmann has also been honored multiple times as part of the President’s Club and as the National Account Manager of the year for Spacelabs Medical and is an active member of DIA.
“We are delighted to welcome Laurie to our team” comments Jean Pierre Wery, President of Crown Bioscience. “We have an ambitious growth strategy for our Translational Service Platforms and Laurie’s hands-on experience with strategic vision in marketing and business development will be instrumental in the effort to drive forward our global operations. Her invaluable perspectives will considerably increase our influence in the global pre-clinical arena, allowing Crown to pursue helping our clients improve clinical outcomes for patients throughout the world.”
This recruitment drive follows recent announcements by Crown Bioscience Inc., including the opening of a new facility in Kannapolis in October 2014, as well as an expansion of the Crown Bioscience UK facility based in Nottingham in January 2015. This activity signals the next stage in Crown’s global strategy to increase access to its service platforms, step up European operations and increase the company’s visibility as a global provider of preclinical CRO services.
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.